Lack of Pharmacokinetic Drug Interaction Between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2005 Sep 29

PMID 16189129

Citations 11

Authors

Marta Boffito

Anton Pozniak

Brian P Kearney

Christopher Higgs

Anita Mathias

Lijie Zhong

Jaymin Shah

Affiliations

Soon will be listed here.

Abstract

A study explored the pharmacokinetics of tenofovir (300 mg administered once daily) and nelfinavir (1,250 mg twice daily) when coadministered in 29 healthy volunteers. Tenofovir, nelfinavir, and M8 pharmacokinetics was unaltered when tenofovir and nelfinavir were coadministered, and tenofovir administration did not affect the M8/nelfinavir area under the concentration-versus-time curve over the dosing interval (AUC(tau)) ratio. No interaction between tenofovir and nelfinavir was observed.

Citing Articles

Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.

Eke A, Shoji K, Best B, Momper J, Stek A, Cressey T Antimicrob Agents Chemother. 2020; 65(3).

PMID: 33318014 PMC: 8092509. DOI: 10.1128/AAC.02168-20.

Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.

Cressey T, Siriprakaisil O, Kubiak R, Klinbuayaem V, Sukrakanchana P, Quame-Amaglo J Int J Infect Dis. 2020; 97:365-370.

PMID: 32553717 PMC: 7392195. DOI: 10.1016/j.ijid.2020.06.037.

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects.

Frost C, Song Y, Yu Z, Wang J, Lee L, Schuster A Clin Pharmacol. 2017; 9:19-28.

PMID: 28260951 PMC: 5327911. DOI: 10.2147/CPAA.S115687.

Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.

Thomford N, Dzobo K, Chopera D, Wonkam A, Skelton M, Blackhurst D Pharmaceuticals (Basel). 2015; 8(3):637-63.

PMID: 26402689 PMC: 4588186. DOI: 10.3390/ph8030637.

The role of drug transporters in the kidney: lessons from tenofovir.

Moss D, Neary M, Owen A Front Pharmacol. 2014; 5:248.

PMID: 25426075 PMC: 4227492. DOI: 10.3389/fphar.2014.00248.

References

Birkus G, Hajek M, Kramata P, Votruba I, Holy A, Otova B . Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*. Antimicrob Agents Chemother. 2002; 46(5):1610-3. PMC: 127178. DOI: 10.1128/AAC.46.5.1610-1613.2002. View

Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R . Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002; 16 Suppl 1:S5-37. DOI: 10.1097/00002030-200203001-00002. View

Kruse G, Esser S, Stocker H, Breske A, Koerber A, Kopperman M . The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Antivir Ther. 2005; 10(2):349-55. View

Gallant J, Staszewski S, Pozniak A, DeJesus E, Suleiman J, Miller M . Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004; 292(2):191-201. DOI: 10.1001/jama.292.2.191. View

Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G . Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br J Clin Pharmacol. 2004; 59(1):38-42. PMC: 1884971. DOI: 10.1111/j.1365-2125.2004.02240.x. View